Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant PK and Safety in Pediatric HAE
NCT01386658Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Time to Peak Concentration at Day 1, Maximum Plasma Concentration at Day 1 and 10 more. Started Jan 2012; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01386658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386658.